Sergey Young
Bold text==Sergey Young==
Sergey Young (born 1971)[1] is a leading figure in the field of human longevity, whose $100 million Longevity Vision Fund supports life-enhancing and prolonging technologies. These include organ bio-printing, genome therapy[2] and Artificial Intelligence-powered drug development and diagnostics. Young is on the Financial Advisory Board for the UK All Party Parliamentary Group on Longevity.[3]
Young’s fund is among the largest in the world in terms of capital specifically targeted at life extension[1] and his overall goal is to extend healthy life expectancy by 20–30 years in the near term. Before founding the Longevity Vision Fund, Young was a venture capitalist with a portfolio that included real estate, food retail, transportation and logistics. A health scare at the age of 42 led him to reassess his life and relaunch his career on a more philanthropic course.[4]
Early Life, Career, Health Emergency
Young was born in the town of Dalnegorsk in what was then the Soviet Union. One of his first jobs was at McKinsey & Company, a global management consulting firm. Later, he co-founded Peak State Ventures, a venture fund that deploys $150 million[2] for investment in, among others, real estate and digital healthcare.
A routine visit to the doctor revealed a chronic heart condition that would have condemned him to a lifetime of chemical statins to control elevated cholesterol levels.[4] Instead, Young transformed his entire approach to diet and health and brought down his lipid levels naturally by 25%.[2] This health scare prompted him to start a new phase of his career.
The Longevity Vision Fund
Young launched the Longevity Vision Fund in 2018[1][5] with the aim of ‘changing the lives of 1 billion people.’[2]
The fund sets out to accelerate the latest breakthroughs in longevity by investing in start-ups and companies that develop technologies, products and services to extend human lifespan and counteract the negative effects of aging. Young also aims to make these technologies ‘scalable’ - accessible not just to the rich but to the general population.[4][5]
Referred to as the LVF, it has attracted $100 million from a spectrum of American and European investors based in London, New York and Silicon Valley[1]. It provides various levels of seed and equity funding to biotech and life extension-focused companies. Its board of advisors include many of the world’s most prominent figures in this sphere: Aubrey de Gray, Joao Pedro de Magalhaes, Richard Faragher and Morten Scheibye-Knudsen.[3][4]
The fund’s investments include a stake in Juvenescence, a UK-based biotech incubator start-up created by billionaire Jim Mellon and valued at $500 million,[2] which is developing what it describes as a “Longevity Ecosystem.” Deep Longevity, another recipient of LVF backing, is using Artificial Intelligence to create an exhaustive cell-by-cell portrait called an 'AgeMetric' depicting an individual's precise biological age, as well as AI 'Longevity Clocks' to predict and pre-empt the insidious mechanisms behind age-related diseases.[6]
In what might once have seemed more in the realm of science fiction, Young is investing in the very real prospect of organ regeneration, which he hopes will allow patients to replace failed or poorly functioning body parts. One of the most striking examples of this is an innovative company, also receiving LVF funding, called LyGenesis.[7] Based in Pittsburgh, Pennsylvania, it is currently working on re-growing the organs of patients ‘in bioreactors inside the body' - a process powered by their own lymph nodes.[8]
In addition, Young is also supporting the development of AI drug discovery, gene therapies, gene editing technologies and regenerative medicine.
In total, Young’s fund has stakes in over 165 different companies, ranging from those exploring revolutionary new approaches to gene therapy to others working to develop advanced AI-enabled diagnostic tools.[9]
XPRIZE and Growing Young
In collaboration with fellow longevity enthusiast Peter Diamandis Young has helped create and sponsor a longevity award called the Age-reversal XPRIZE.[3][4] The objective is to create a global competition between teams from 50 countries, all participating to discover and develop age reversal solutions.[10]
Young’s upcoming book is titled "The Science and Technology of Growing Young.”[11] The book represents a scientific look into the future of longevity and covers key longevity and health tech breakthroughs. The book is based on Young’s framework that he calls the 'Three Horizons of Longevity.'[1][2][4]
Personal Life
Sergey Young is married with four children.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Paris Match - Cet homme espère vivre jusqu'à 200 ans et... trouver un vaccin contre le Covid-19,English Translation - Paris Match - The Man Who Wants to Live to 200 Years... and to Find a Vaccine for Covid-19
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 AMEinfo - Longevity Lessons from Sergey Young: “My Goal is to Extend Lifespans for 1 Billion People”
- ↑ 3.0 3.1 3.2 Technowize -Most Innovative People to Watch in 2020
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Lifespan.io - Sergey Young and the Longevity Vision Fund
- ↑ 5.0 5.1 AMEinfo - Exclusive: Longevity Vision Fund invests into record-breaking AI Drug Discovery Company
- ↑ Yahoo - Deep Longevity Repurposes a Blood Aging Clock for Saliva Samples
- ↑ Forbes - What Living To 150 Might Look Like
- ↑ AMEinfo - Three Horizons of Longevity Innovation
- ↑ Forbes - Aging Is A Feature, Not A Bug
- ↑ Forbes - 'Extraordinary' Breakthroughs In Anti-Aging Research 'Will Happen Faster Than People Think'
- ↑ Forbes - The Science and Technology of Growing Young
External links
This article "Sergey Young" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sergey Young. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
